TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The FDA granted accelerated approval to dostarlimab for select patients with operable stage II or III dMMR/MSI-H rectal cancer. Patients who achieve a complete response may be able to avoid surgery and other standard treatments, but long-term relapse risk is not yet known and a confirmatory trial may be required.
The U.S. Food and Drug Administration on Monday granted accelerated approval to dostarlimab (Jemperli) for select patients with operable stage II or III rectal cancer whose tumors are mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H). The drug may allow patients who achieve a complete response to avoid surgery and potentially chemotherapy and radiation, but the long-term risk of recurrence in this setting remains unknown.
The approval applies to a biomarker-defined subgroup estimated to make up about 3% of locally advanced rectal cancers. Dostarlimab is a PD-1 inhibitor, a type of immunotherapy. The approval does not mean every eligible patient will avoid surgery: the possibility depends on whether treatment produces a complete response, and patients require clinical assessment and follow-up.
The FDA decision was supported by the AZUR-1 trial, which studied dostarlimab in patients with dMMR/MSI-H rectal cancer and other solid tumors. According to the company announcement, an exploratory analysis found that 76% of evaluable patients had no evidence of cancer at least a year after treatment. After a median follow-up of more than two years, the company reported no recurrences. These findings are specific to the reported analysis and follow-up period; they do not establish that recurrence is impossible.
Most adverse events reported in AZUR-1 were grade 1 or 2. The most common were fatigue, affecting 32% of patients; rash, 22%; diarrhea, 18%; and itching, 17%. The report also listed individual grade 3 events involving diabetes, lung infection, hypothyroidism, encephalitis and neutropenia, and one grade 4 case of febrile neutropenia. The prescribing information warns of possible immune-mediated adverse events.
A Chance to Avoid Major Treatment
For eligible patients who have a complete response, the approval creates a treatment path that may spare them some or all of the usual combination of chemotherapy, radiation and surgery. Rectal cancer surgery can have lasting effects on daily life, and avoiding it could matter to patients weighing cancer control against treatment-related consequences. The approval offers a potential option, not a guarantee of avoiding those treatments.
The designation also makes biomarker testing at diagnosis relevant to identifying people who might qualify. Michael Sapienza, CEO of the Colorectal Cancer Alliance, said testing will be essential to finding potentially eligible patients and helping them understand their choices. The decision is limited to the specified tumor markers and stages; it does not extend the drug to all rectal cancers.
dMMR MSI-H rectal cancer biomarker testing kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Evidence and Approval Scope
The AZUR-1 findings underpinning the decision concern tumors with dMMR/MSI-H biology, which can respond differently to immunotherapy than other cancers. Andrea Cercek of Memorial Sloan Kettering Cancer Center, the trial’s principal investigator, previously said neoadjuvant PD-1 inhibition could potentially remove the need for chemotherapy, radiation and surgery for a small share of solid tumors. That statement described potential, rather than a proven outcome for every patient.
Dostarlimab already has several approved uses in endometrial cancer and is approved for previously treated dMMR recurrent or advanced solid tumors, according to the source report. The new decision adds an indication for selected operable rectal cancer patients. Because the FDA granted accelerated approval, continued approval may depend on verification and description of clinical benefit in a confirmatory trial.
“For certain types of rectal cancer, this approval represents a groundbreaking option that avoids surgery, radiation, and chemotherapy.”
— Angelo de Claro, director of the FDA’s Oncology Center of Excellence
Long-Term Control Still Needs Study
The available report does not establish how often cancer may return after the reported follow-up period. Although the company said no recurrences had been reported after a median follow-up of more than two years, the FDA labeling states that the long-term relapse risk with dostarlimab in this setting is unknown. A lack of reported recurrence so far is not proof that relapse cannot occur.
The source material does not provide the full trial design, the total number of patients in the exploratory analysis, or detailed results for rectal cancer separately from other tumor types. It also does not specify how clinicians will determine the timing of surgery or other treatment for an individual patient who does not achieve a complete response. Those details should not be inferred from the approval announcement.
Confirmatory Evidence and Patient Selection
A confirmatory trial may be needed to verify and describe the clinical benefit, as indicated in the drug’s labeling. Further follow-up should clarify how durable complete responses are and how the treatment performs over a longer period. The available source does not give a timetable for that evidence or identify a specific next trial milestone.
For patients, the immediate practical step is determining whether the tumor has the dMMR/MSI-H markers and discussing the approved option with their cancer care team. Eligibility does not predict an individual response, and the treatment decision must account for the possibility of adverse events and the need for monitoring. The FDA announcement does not say that standard treatments are no longer appropriate for patients who do not respond completely.
Key Questions
Who is eligible for the new dostarlimab indication?
The approval covers selected patients with operable stage II or III rectal cancer whose tumors are dMMR/MSI-H. A clinician must assess whether a patient meets the indication; the source report estimates this subgroup represents about 3% of locally advanced rectal cancers.
Does the approval mean patients can skip surgery?
Not automatically. Patients who achieve a complete response may be able to avoid surgery, and potentially chemotherapy and radiation. The approval does not guarantee a response or establish that every patient can forgo standard treatments.
What results were reported from AZUR-1?
In an exploratory analysis reported by the company, 76% of evaluable patients had no evidence of cancer at least a year after treatment. The company said no recurrences had been reported after a median follow-up of more than two years; longer-term risk remains unknown.
What side effects were reported?
Common reported events included fatigue, rash, diarrhea and itching. The trial also recorded serious events, including one grade 4 case of febrile neutropenia. Prescribing information warns that dostarlimab can cause immune-mediated adverse events.
Is the approval final without further study?
The FDA granted accelerated approval. The drug’s labeling says continued approval may depend on verification and description of clinical benefit in a confirmatory trial.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
